Trevi Therapeutics (TRVI) Tops Q3 EPS by 5c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.12), $0.05 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FirstCash to acquire UK pawn operator Ramsdens for £206 million
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs